Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Sequenom, Mayo Medical Laboratories; Enigma Diagnostics; Bioline; Atlas Genetics

NEW YORK (GenomeWeb News) – Sequenom said this week that Mayo Medical Laboratories, the reference laboratory for the Mayo Clinic, will offer access to Sequenom's MaterniT21 Plus test for fetal aneuploidies. Mayo Medical Laboratories provides diagnostic tests to more than 5,000 healthcare institutions around the world.

Enigma Diagnostics CE marked it EnigmaML system and the company’s first FluAB-RSV diagnostic assay. The real-time PCR-based system is a raw sample-to-result instrument, which delivers results equivalent to central laboratory standards in up to 70 minutes, Enigma said. The assay detects all currently circulating influenza and RSV viruses from nasopharygeal swab samples.

Meridian Bioscience subsidiary Bioline has opened an office in Singapore to support and grow its business in the region. Bioline will provide direct sales, technical support, and training to its existing customers. It said it also can offer same-day delivery to many of its customers in Singapore.

Atlas Genetics completed development of the Atlas io Reader and is entering pilot manufacturing of the instrument ahead of clinical studies to support the company’s submission for regulatory approval in Europe. The io Reader, developed with The Technology Partnership, automates sample preparation, DNA amplification, and electrochemical detection.

In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

The Scan

And a Fourth?

A fourth dose of the Pfizer-BioNTech SARS-CoV-2 vaccine in an Israeli study increased antibody levels but did not prevent Omicron variant infections, according to the Financial Times.

For Better Science Software

A virtual institute funded by former Google CEO Eric Schmidt's philanthropy aims to lure software engineers to academia, Science reports.

Recommendation Explanations

The New York Times writes that the US Centers for Disease Control and Prevention is straining to both make and explain decisions based on limited information.

Genome Research Papers on De Novo Mutation Rates, Polyploid Genotyping, Oncogene Epigenomic Translocation

In Genome Research this week: de novo mutations rates in hemoglobin subunits, analysis of variant calling methods for polyploid plants, and more.